Back to database

AOD-9604

Also known as: Anti-Obesity Drug 9604

GLP-1 / Weight LossTGA Approved (Australia, oral)SubcutaneousOral

A modified fragment of human growth hormone (amino acids 177-191) that stimulates lipolysis without the growth-promoting or diabetogenic effects of full GH.

Molecular Weight

1815.1 Da

Half-Life

~6-8 hours

Sequence

hGH fragment 177-191 (modified)

Mechanism of Action

Mimics the lipolytic region of GH. Stimulates fat breakdown in adipose tissue, inhibits lipogenesis, and does not affect blood sugar or growth.

Dosing Protocol

250-500 mcg/day subcutaneous, on an empty stomach. Cycle 12 weeks on, 4 weeks off.

Open peptide calculator
Reconstitution

5mg vial + 2mL BAC water = 2500 mcg/mL.

Storage

Lyophilized: -20°C. Reconstituted: 2-8°C.

Side Effects
  • ●Generally well-tolerated
  • ●Mild injection site reactions
  • ●Headache (rare)
Key Research Findings
  • ●Reduced body fat without affecting IGF-1 levels
  • ●TGA approval for osteoarthritis treatment (oral)
  • ●No effect on blood glucose in clinical studies

Research Use Only

This information is provided for educational and research purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before using any research compounds.